Figure 4From: Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor Kaplan-Meier of survival based on cytogenetic or hematologic follow-up. This figure demonstrates that the survival of patients who were able to obtain cytogenetic follow-up was superior to that of patients who only obtained hematologic follow-up.Back to article page